While AGD-tau may be preventive against AD-related phenotypes by lowering tau aggregation and propagation at Stage I, the wide-spread AGD-tau at Stage III may cause cognitive decline independently of the more common amyloid and tau pathology detected in AD. Here, MAPT is linked to Alzheimer disease.